NRF2 Is One of the Players Involved in Bone Marrow Mediated Drug Resistance in Multiple Myeloma

Gene-expression signature regulated by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell cancer

(2018) Akhileshwar Namani et al.   BMC CANCER

Resistance to proteasome inhibitors and other targeted therapies in myeloma

(2018) Craig T. Wallington-Beddoe et al.   BRITISH JOURNAL OF HAEMATOLOGY

NRF2 and the Hallmarks of Cancer

(2018) Montserrat Rojo de la Vega et al.   CANCER CELL

The Multiple Myeloma Drug Pipeline—2018: A Review of Small Molecules and Their Therapeutic Targets

(2018) Hanley N. Abramson   Clinical Lymphoma Myeloma & Leukemia

The adipose organ and multiple myeloma: Impact of adipokines on tumor growth and potential sites for therapeutic intervention

(2018) Alessandro Allegra et al.   European Journal of Internal Medicine

Pharmacological Targeting of Cell Cycle, Apoptotic and Cell Adhesion Signaling Pathways Implicated in Chemoresistance of Cancer Cells

(2018) Dauren Alimbetov et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Metabolic Features of Multiple Myeloma

(2018) et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Old and Young Actors Playing Novel Roles in the Drama of Multiple Myeloma Bone Marrow Microenvironment Dependent Drug Resistance

(2018) Sabrina Manni et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies

(2018) Wolfgang Willenbacher et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Repurposing of the CDK inhibitor PHA-767491 as a NRF2 inhibitor drug candidate for cancer therapy via redox modulation

(2018) Hsiu-Yu Liu et al.   INVESTIGATIONAL NEW DRUGS

Adipokines, adiposity, and bone marrow adipocytes: Dangerous accomplices in multiple myeloma

(2018) Emma V. Morris et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Targeting the tumour stroma to improve cancer therapy

(2018) Kenneth C. Valkenburg et al.   Nature Reviews Clinical Oncology

Protection by dimethyl fumarate against diabetic cardiomyopathy in type 1 diabetic mice likely via activation of nuclear factor erythroid-2 related factor 2

(2018) Xinyue Hu et al.   TOXICOLOGY LETTERS

The potential function of microRNAs as biomarkers and therapeutic targets in multiple myeloma (Review)

(2018) Bingying Zhu et al.   Oncology Letters

Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials

(2018) Sikander Ailawadhi et al.   Blood Cancer Journal

Compromised functionality of monocyte-derived dendritic cells in multiple myeloma patients may limit their use in cancer immunotherapy

(2018) Prajakta Shinde et al.   Scientific Reports

Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials

(2018) Yanhua Zheng et al.   Journal of Immunology Research

Soluble and Cell–Cell-Mediated Drivers of Proteasome Inhibitor Resistance in Multiple Myeloma

(2018) Mariah L. Farrell et al.   Frontiers in Endocrinology

Predicting treatment benefit in multiple myeloma through simulation of alternative treatment effects

(2018) Joske Ubels et al.   Nature Communications

Adipocytes Promote Early Steps of Breast Cancer Cell Dissemination via Interleukin-8

(2018) Gabriela Vazquez Rodriguez et al.   Frontiers in Immunology

Red ginseng-derived saponin fraction suppresses the obesity-induced inflammatory responses via Nrf2-HO-1 pathway in adipocyte-macrophage co-culture system

(2018) Chae Young Kim et al.   BIOMEDICINE & PHARMACOTHERAPY

Corrigendum to “Cytoplasmic localization of Nrf2 promotes colorectal cancer with more aggressive tumors via upregulation of PSMD4” [Free Radic. Biol. Med. 95 (2016) 121–32]

(2017) Po-Lin Lin et al.   FREE RADICAL BIOLOGY AND MEDICINE

From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives

(2017) Francesca Gay et al.   HAEMATOLOGICA

Various Mechanisms Involve the Nuclear Factor (Erythroid-Derived 2)-Like (NRF2) to Achieve Cytoprotection in Long-Term Cisplatin-Treated Urothelial Carcinoma Cell Lines

(2017) Margaretha Skowron et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Role of epigenetics-microRNA axis in drug resistance of multiple myeloma

(2017) Nasrin Rastgoo et al.   Journal of Hematology & Oncology

Mesenchymal stem cells: key players in cancer progression

(2017) Sarah M. Ridge et al.   Molecular Cancer

Brusatol overcomes chemoresistance through inhibition of protein translation

(2017) Bryan Harder et al.   MOLECULAR CARCINOGENESIS

Curcumin prevents reperfusion injury following ischemic stroke in rats via inhibition of NF-κB, ICAM-1, MMP-9 and caspase-3 expression

(2017) Wei Li et al.   Molecular Medicine Reports

Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials

(2017) Jean-Samuel Boudreault et al.   Expert Review of Hematology

Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression

(2017) Patrizia Mondello et al.   Oncotarget

Pirfenidone attenuates bleomycin-induced pulmonary fibrosis in mice by regulating Nrf2/Bach1 equilibrium

(2017) Yuan Liu et al.   BMC Pulmonary Medicine

Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma

(2017) Mark E. Issa et al.   Clinical Epigenetics

From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives

(2017) Francesca Gay et al.   HAEMATOLOGICA

Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine Secretion

(2017) Kim De Veirman et al.   Cancer Immunology Research

Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells

(2017) Rachel M. Gibbons Johnson et al.   Frontiers in Immunology

T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma

(2016) S. A. Ali et al.   BLOOD

Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling

(2016) Xing-Ding Zhang et al.   CANCER CELL

Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapy

(2016) Indu R. Ramachandran et al.   CANCER LETTERS

Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth

(2016) Renate Burger et al.   HAEMATOLOGICA

Isovitexin Exerts Anti-Inflammatory and Anti-Oxidant Activities on Lipopolysaccharide-Induced Acute Lung Injury by Inhibiting MAPK and NF-κB and Activating HO-1/Nrf2 Pathways

(2016) Hongming Lv et al.   International Journal of Biological Sciences

Myeloid-derived suppressor cells as effectors of immune suppression in cancer

(2016) Athalia Rachel Pyzer et al.   INTERNATIONAL JOURNAL OF CANCER

Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma

(2016) Yusuke Furukawa et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Multiple myeloma and persistence of drug resistance in the age of novel drugs (Review)

(2016) SABNA RAJEEV KRISHNAN et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Glabridin Alleviates the Toxic Effects of Methylglyoxal on Osteoblastic MC3T3-E1 Cells by Increasing Expression of the Glyoxalase System and Nrf2/HO-1 Signaling and Protecting Mitochondrial Function

(2016) Eun Mi Choi et al.   JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY

The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment

(2016) F Fan et al.   LEUKEMIA

Calycosin suppresses expression of pro-inflammatory cytokines via the activation of p62/Nrf2-linked heme oxygenase 1 in rheumatoid arthritis synovial fibroblasts

(2016) Xiaohui Su et al.   PHARMACOLOGICAL RESEARCH

The Dual Roles of NRF2 in Cancer

(2016) Silvia Menegon et al.   TRENDS IN MOLECULAR MEDICINE

Role of interleukin-6 in cancer progression and therapeutic resistance

(2016) Neeraj Kumari et al.   TUMOR BIOLOGY

Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription

(2016) Eri H. Kobayashi et al.   Nature Communications

Role of micro-RNAs in drug resistance of multiple myeloma

(2016) Jahangir Abdi et al.   Oncotarget

The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential

(2016) Liesbeth Bieghs et al.   Oncotarget

Granulocytic myeloid-derived suppressor cells promote angiogenesis in the context of multiple myeloma

(2016) Marilène Binsfeld et al.   Oncotarget

Microenvironment drug resistance in multiple myeloma: emerging new players

(2016) Lucia Di Marzo et al.   Oncotarget

Noncanonical SQSTM1/p62-Nrf2 pathway activation mediates proteasome inhibitor resistance in multiple myeloma cells via redox, metabolic and translational reprogramming

(2016) Irene Riz et al.   Oncotarget

Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth

(2016) Renate Burger et al.   HAEMATOLOGICA

The oncometabolite R-2-hydroxyglutarate activates NF-κB-dependent tumor-promoting stromal niche for acute myeloid leukemia cells

(2016) Jing-Yi Chen et al.   Scientific Reports

Dissecting molecular cross-talk between Nrf2 and NF-κB response pathways

(2015) Joanna D. Wardyn et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Keap1/Nrf2 pathway in the frontiers of cancer and non-cancer cell metabolism

(2015) Dionysios V. Chartoumpekis et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

How I treat high-risk myeloma

(2015) S. Lonial et al.   BLOOD

Nrf2 is a potential prognostic marker and promotes proliferation and invasion in human hepatocellular carcinoma

(2015) Mingxin Zhang et al.   BMC CANCER

Impact of access to NCI- and NCCN-designated cancer centers on outcomes for multiple myeloma patients: A SEER registry analysis

(2015) Sikander Ailawadhi et al.   CANCER

SnapShot: Multiple Myeloma

(2015) Esteban Braggio et al.   CANCER CELL

Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma

(2015) J.-J. Zhao et al.   CANCER RESEARCH

miRNA-202 in bone marrow stromal cells affects the growth and adhesion of multiple myeloma cells by regulating B cell-activating factor

(2015) Xianjuan Shen et al.   CLINICAL AND EXPERIMENTAL MEDICINE

NRF2 Pathway Activation and Adjuvant Chemotherapy Benefit in Lung Squamous Cell Carcinoma

(2015) D. W. Cescon et al.   CLINICAL CANCER RESEARCH

Myeloid-derived suppressor cells in immunity and autoimmunity

(2015) Hui Yang et al.   Expert Review of Clinical Immunology

p62 links autophagy and Nrf2 signaling

(2015) Tao Jiang et al.   FREE RADICAL BIOLOGY AND MEDICINE

Molecular pathogenesis of multiple myeloma

(2015) Yusuke Furukawa et al.   International Journal of Clinical Oncology

The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple Myeloma

(2015) Bingzong Li et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected

(2015) Douglas Marvel et al.   JOURNAL OF CLINICAL INVESTIGATION

Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities

(2015) G. Shay et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Multiple myeloma

(2015) Christoph Röllig et al.   LANCET

Autocrine amplification of immature myeloid cells by IL-6 in multiple myeloma-infiltrated bone marrow

(2015) T Matthes et al.   LEUKEMIA

Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells

(2015) Kim De Veirman et al.   Oncotarget

Activation of NRF2 by p62 and proteasome reduction in sphere-forming breast carcinoma cells

(2015) In-geun Ryoo et al.   Oncotarget

Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma

(2015) Wen-Chi Yang et al.   Biomed Research International

Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms

(2015) Jahangir Abdi et al.   Oncotarget

Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype

(2015) Katia Beider et al.   Oncotarget

Reactive Oxygen Species Regulate Hematopoietic Stem Cell Self-Renewal, Migration and Development, As Well As Their Bone Marrow Microenvironment

(2014) Aya Ludin et al.   ANTIOXIDANTS & REDOX SIGNALING

Nrf2 Overexpression Predicts Prognosis and 5-FU Resistance in Gastric Cancer

(2014) Xiu-Feng Hu et al.   Asian Pacific Journal of Cancer Prevention

The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma

(2014) A. Spencer et al.   BLOOD

Myeloid Lineage-Specific Deletion of Antioxidant System Enhances Tumor Metastasis

(2014) K. Hiramoto et al.   Cancer Prevention Research

NRF2-driven miR-125B1 and miR-29B1 transcriptional regulation controls a novel anti-apoptotic miRNA regulatory network for AML survival

(2014) N M Shah et al.   CELL DEATH AND DIFFERENTIATION

A HGF/cMET Autocrine Loop Is Operative in Multiple Myeloma Bone Marrow Endothelial Cells and May Represent a Novel Therapeutic Target

(2014) A. Ferrucci et al.   CLINICAL CANCER RESEARCH

Toll-Like Receptors in Human Multiple Myeloma: New Insight into Inflammation-Related Pathogenesis

(2014) J. Abdi et al.   CURRENT MOLECULAR MEDICINE

Complexity and challenges in defining myeloid-derived suppressor cells

(2014) Vera Damuzzo et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells

(2014) Jiro Kikuchi et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Cancer-Expanded Myeloid-Derived Suppressor Cells Induce Anergy of NK Cells through Membrane-Bound TGF- 1

(2014) H. Li et al.   JOURNAL OF IMMUNOLOGY

Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice

(2014) J.-I. Youn et al.   JOURNAL OF IMMUNOLOGY

PKA/AMPK signaling in relation to adiponectin’s antiproliferative effect on multiple myeloma cells

(2014) E A Medina et al.   LEUKEMIA

Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma

(2014) James Favaloro et al.   LEUKEMIA & LYMPHOMA

Current treatment landscape for relapsed and/or refractory multiple myeloma

(2014) Meletios A. Dimopoulos et al.   Nature Reviews Clinical Oncology

Eosinophils and Megakaryocytes Support the Early Growth of Murine MOPC315 Myeloma Cells in Their Bone Marrow Niches

(2014) David Wong et al.   PLoS One

URI regulates tumorigenicity and chemotherapeutic resistance of multiple myeloma by modulating IL-6 transcription

(2014) J-L Fan et al.   Cell Death & Disease

Multiple myeloma maintenance therapy: A review of the pharmacologic treatment

(2014) Brandon R Shank et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Adipose tissue and adipocytes support tumorigenesis and metastasis

(2013) Kristin M. Nieman et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans

(2013) G. T. Gorgun et al.   BLOOD

Pharmaco-miR: linking microRNAs and drug effects

(2013) J. L. Rukov et al.   BRIEFINGS IN BIOINFORMATICS

Osteoclast-Derived Coupling Factors in Bone Remodeling

(2013) Kim Henriksen et al.   CALCIFIED TISSUE INTERNATIONAL

Redox activation of Nrf2 & NF-κB: A double end sword?

(2013) Mabel Buelna-Chontal et al.   CELLULAR SIGNALLING

Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth

(2013) E. Leone et al.   CLINICAL CANCER RESEARCH

Myeloid-Derived Suppressor Cells Enhance Stemness of Cancer Cells by Inducing MicroRNA101 and Suppressing the Corepressor CtBP2

(2013) Tracy X. Cui et al.   IMMUNITY

Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways

(2013) Patrick L. Raber et al.   INTERNATIONAL JOURNAL OF CANCER

Critical Role of AKT Protein in Myeloma-induced Osteoclast Formation and Osteolysis

(2013) Huiling Cao et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Myeloid-Derived Suppressor Cells Regulate Growth of Multiple Myeloma by Inhibiting T Cells in Bone Marrow

(2013) I. R. Ramachandran et al.   JOURNAL OF IMMUNOLOGY

Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease

(2013) Stacey Ruiz et al.   KIDNEY INTERNATIONAL

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

(2013) S K Kumar et al.   LEUKEMIA

Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications

(2013) C C Bjorklund et al.   LEUKEMIA

Endoplasmic Reticulum Stress and the Unfolded Protein Response: Targeting the Achilles Heel of Multiple Myeloma

(2013) L. Vincenz et al.   MOLECULAR CANCER THERAPEUTICS

Roles Nrf2 Plays in Myeloid Cells and Related Disorders

(2013) Eri Kobayashi et al.   Oxidative Medicine and Cellular Longevity

Characterization of the Toll-like Receptor Expression Profile in Human Multiple Myeloma Cells

(2013) Jahangir Abdi et al.   PLoS One

Novel Adipokines and Bone Metabolism

(2013) Yuan Liu et al.   International Journal of Endocrinology

Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells

(2013) D Chiron et al.   Blood Cancer Journal

The role of endoplasmic reticulum stress in maintaining and targeting multiple myeloma: a double-edged sword of adaptation and apoptosis

(2013) Shai White-Gilbertson et al.   Frontiers in Genetics

Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma

(2012) D. J. Kuhn et al.   BLOOD

Bortezomib induces heme oxygenase-1 expression in multiple myeloma

(2012) Lawrence N. Barrera et al.   CELL CYCLE

Targeting of Adhesion Molecules as a Therapeutic Strategy in Multiple Myeloma

(2012) Paola Neri et al.   CURRENT CANCER DRUG TARGETS

Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma

(2012) H Tamura et al.   LEUKEMIA

PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma

(2012) Y Zheng et al.   LEUKEMIA

Circulating microRNA expression is associated with genetic subtype and survival of multiple myeloma

(2012) Jing-jing Huang et al.   MEDICAL ONCOLOGY

Differential macrophage programming in the tumor microenvironment

(2012) Brian Ruffell et al.   TRENDS IN IMMUNOLOGY

Cancer stem cells, tumor dormancy, and metastasis

(2012) Purvi Patel et al.   Frontiers in Endocrinology

The Keap1–Nrf2 system in cancers: stress response and anabolic metabolism

(2012) Yoichiro Mitsuishi et al.   Frontiers in Oncology

Pathogenesis of Myeloma

(2011) Kenneth C. Anderson et al.   Annual Review of Pathology-Mechanisms of Disease

Integrin  7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion

(2011) P. Neri et al.   BLOOD

A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells

(2011) S. Solito et al.   BLOOD

Myeloid-Derived Suppressor Cell Inhibition of the IFN Response in Tumor-Bearing Mice

(2011) B. L. Mundy-Bosse et al.   CANCER RESEARCH

Up-regulation ofmiR-21Mediates Resistance to Trastuzumab Therapy for Breast Cancer

(2011) Chang Gong et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells

(2011) Barbara Molon et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells

(2011) Mu Hao et al.   Journal of Hematology & Oncology

Functional characterization of human Cd33+ And Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines

(2011) Melissa G Lechner et al.   Journal of Translational Medicine

Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation

(2011) Xudong Wang et al.   LEUKEMIA & LYMPHOMA

Multiple Myeloma

(2011) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer Chemoprevention Mechanisms Mediated Through the Keap1–Nrf2 Pathway

(2010) John D. Hayes et al.   ANTIOXIDANTS & REDOX SIGNALING

Chronic Granulomatous Disease: Lessons from a Rare Disorder

(2010) Brahm H. Segal et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Nrf2-deficiency creates a responsive microenvironment for metastasis to the lung

(2010) Hironori Satoh et al.   CARCINOGENESIS

Anti-inflammatory Triterpenoid Blocks Immune Suppressive Function of MDSCs and Improves Immune Response in Cancer

(2010) S. Nagaraj et al.   CLINICAL CANCER RESEARCH

Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia

(2010) Dan-Dan Feng et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Survivin is upregulated in myeloma cell lines cocultured with mesenchymal stem cells

(2010) Xiaofang Wang et al.   LEUKEMIA RESEARCH

Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-κB activity in myeloma cells

(2010) Stephanie Markovina et al.   Molecular Cancer

TLR4/MyD88-induced CD11b+Gr-1intF4/80+ non-migratory myeloid cells suppress Th2 effector function in the lung

(2010) M Arora et al.   Mucosal Immunology

Adhesion molecules—The lifelines of multiple myeloma cells

(2010) Ben-Zion Katz   SEMINARS IN CANCER BIOLOGY

Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function

(2010) Thomas Condamine et al.   TRENDS IN IMMUNOLOGY

Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis

(2009) Y. Zheng et al.   BLOOD

 1 Integrin Adhesion Enhances IL-6-Mediated STAT3 Signaling in Myeloma Cells: Implications for Microenvironment Influence on Tumor Survival and Proliferation

(2009) K. H. Shain et al.   CANCER RESEARCH

Sunitinib Inhibition of Stat3 Induces Renal Cell Carcinoma Tumor Cell Apoptosis and Reduces Immunosuppressive Cells

(2009) H. Xin et al.   CANCER RESEARCH

Monocyte Dependent Regulation of Autoimmune Inflammation

(2009) Lindsay Nicholson et al.   CURRENT MOLECULAR MEDICINE

Structural basis for recruitment of CBP/p300 coactivators by STAT1 and STAT2 transactivation domains

(2009) Jonathan M Wojciak et al.   EMBO JOURNAL

Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF

(2009) Luigi Dolcetti et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Myeloid-derived suppressor cell activation by combined LPS and IFN-γ treatment impairs DC development

(2009) Verena Greifenberg et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Mechanism Regulating Reactive Oxygen Species in Tumor-Induced Myeloid-Derived Suppressor Cells

(2009) C. A. Corzo et al.   JOURNAL OF IMMUNOLOGY

Contribution of bone microenvironment to leukemogenesis and leukemia progression

(2009) F Ayala et al.   LEUKEMIA

Environmental-mediated drug resistance: a target for multiple myeloma therapy

(2009) Kenneth H Shain et al.   Expert Review of Hematology

Activation of Nrf2-antioxidant signaling attenuates NFκB-inflammatory response and elicits apoptosis

(2008) Wenge Li et al.   BIOCHEMICAL PHARMACOLOGY

NF-κB/p65 antagonizes Nrf2-ARE pathway by depriving CBP from Nrf2 and facilitating recruitment of HDAC3 to MafK

(2008) Guang-Hui Liu et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Pleiotrophin produced by multiple myeloma induces transdifferentiation of monocytes into vascular endothelial cells: a novel mechanism of tumor-induced vasculogenesis

(2008) H. Chen et al.   BLOOD

HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma

(2008) Ramadevi Nimmanapalli et al.   BRITISH JOURNAL OF HAEMATOLOGY

Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders

(2008) Shaji K. Kumar et al.   BRITISH JOURNAL OF HAEMATOLOGY

The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance

(2008) M. B. Meads et al.   CLINICAL CANCER RESEARCH

Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives

(2008) Paulo C. Rodríguez et al.   IMMUNOLOGICAL REVIEWS

Stat3 mediates myeloid cell–dependent tumor angiogenesis in mice

(2008) Maciej Kujawski et al.   JOURNAL OF CLINICAL INVESTIGATION

Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein

(2008) Pingyan Cheng et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Bone marrow microenvironment and the identification of new targets for myeloma therapy

(2008) K Podar et al.   LEUKEMIA

Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma

(2008) K Hatano et al.   ONCOGENE

Nrf2 signaling: An adaptive response pathway for protection against environmental toxic insults

(2007) W OSBURN et al.   MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH